Healthcare / Animal HealthTechnical Analysis Guide

ZTS Stock Analysis

Zoetis Inc.

💡 Quick Answer

Across 4 APEX technical signals, ZTS is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.

Companion Animal Growth: Pet humanization tailwindRSI Behavior: Premium compounder 45-70Livestock Segment: Protein demand + food security

Zoetis is the world's largest animal health company. A Pfizer spin-off. Developing vaccines, medicines, and diagnostic tools for livestock and companion animals (dogs, cats, horses). Its companion animal business (drugs for pets) has grown dramatically with pet ownership trends and the humanization of pets. Simparica Trio (flea, tick, and heartworm prevention) and Cytopoint (atopic dermatitis treatment) are blockbuster products with $1B+ annual sales. The livestock segment serves poultry, swine, and cattle producers globally.

LIVE CHART·ZTS. DailyPowered by TradingView

📊 Open ZTS on TradingView ↗Affiliate link

Get live ZTS signal analysis

APEX runs 8 signals on ZTS in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze ZTS Now →

Why Do Traders Watch ZTS?

ZTS is a premium healthcare compounder with ATR of 2-4%, insulated from human drug pricing policy risk. It benefits from two durable trends: pet humanization (owners spending more on pet healthcare) and global protein demand growth (driving livestock health spending). Post-earnings moves of 4-7% are typical. ZTS is the go-to trade for healthcare exposure without Medicare/Medicaid policy risk, making it a favored defensive holding during healthcare regulatory uncertainty cycles.

Is ZTS a Buy Right Now? Current Signal Readings

📊Companion Animal GrowthPet humanization tailwind

Zoetis's companion animal segment (45%+ of revenue) has grown at 10-15% annually as pet ownership surged post-COVID and owners increasingly treat pets with the same medical standards as humans. Products like Librela (monoclonal antibody for dog pain) and Solensia (cat pain) represent a new category of premium biologics for pets that carry human-drug-level margins.

📊RSI BehaviorPremium compounder 45-70

ZTS's consistent earnings delivery creates a high RSI floor similar to other premium healthcare compounders. RSI dips to 45-48 during broad healthcare selloffs. Where animal health fundamentals are completely unaffected by human insurance policy. Have been some of the most reliable sector-rotation-driven entry points in the past five years.

📊Livestock SegmentProtein demand + food security

Zoetis's livestock business provides vaccines and medicines for pigs, poultry, and cattle. Essential for global food security. Avian influenza outbreaks are a periodic catalyst that drives emergency vaccine demand from poultry producers. Strong livestock segment performance during disease outbreak cycles provides counter-cyclical revenue that offsets any near-term companion animal softness.

💊Innovation PipelineBiologics for pets

ZTS's R&D pipeline of veterinary biologics. Monoclonal antibodies, mRNA vaccines for pets, and gene therapies for animals. Is the highest-margin product category in animal health. Each regulatory approval of a novel biologic (particularly in pain management and oncology for companion animals) adds $200-500M in peak annual revenue potential at 70%+ gross margins.

📋 ZTS Key Stats for Traders

⚡ATR (14-day)2-4% of price

📦Avg daily volume~2-4 million shares

🎯Key metricCompanion animal revenue growth

📅Post-earnings move4-7% typical

🔗 Related Stocks

IDXX ABT TMO LLY

Run a live ZTS analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze ZTS Free →

📊 Advanced charting for ZTS on TradingView ↗

💬 Frequently Asked Questions. ZTS

QIs ZTS a good stock to buy right now?

AWhether ZTS is a buy depends on its current technical positioning. ZTS is a premium healthcare compounder with ATR of 2-4%, insulated from human drug pricing policy risk. It benefits from two durable trends: pet humanization (owners spending more on pet healthcare) and global protein demand growth (driving livestock health spending). Post-earnings moves of 4-7% are typical. ZTS is the go-to trade for healthcare exposure without Medicare/Medicaid policy risk, making it a favored defensive holding during healthcare regulatory uncertainty cycles. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for ZTS?

AThe four key signals for ZTS are: Companion Animal Growth (Pet humanization tailwind). Zoetis's companion animal segment (45%+ of revenue) has grown at 10-15% annually as pet ownership surged post-COVID and owners increasingly treat pets with the same medical standards as humans. Products like Librela (monoclonal antibody for dog pain) and Solensia (cat pain) represent a new category of premium biologics for pets that carry human-drug-level margins.. RSI Behavior (Premium compounder 45-70). ZTS's consistent earnings delivery creates a high RSI floor similar to other premium healthcare compounders. RSI dips to 45-48 during broad healthcare selloffs. Where animal health fundamentals are completely unaffected by human insurance policy. Have been some of the most reliable sector-rotation-driven entry points in the past five years.. Livestock Segment (Protein demand + food security). Zoetis's livestock business provides vaccines and medicines for pigs, poultry, and cattle. Essential for global food security. Avian influenza outbreaks are a periodic catalyst that drives emergency vaccine demand from poultry producers. Strong livestock segment performance during disease outbreak cycles provides counter-cyclical revenue that offsets any near-term companion animal softness.. Innovation Pipeline (Biologics for pets). ZTS's R&D pipeline of veterinary biologics. Monoclonal antibodies, mRNA vaccines for pets, and gene therapies for animals. Is the highest-margin product category in animal health. Each regulatory approval of a novel biologic (particularly in pain management and oncology for companion animals) adds $200-500M in peak annual revenue potential at 70%+ gross margins.

QWhat is ZTS's RSI telling traders right now?

AZTS's consistent earnings delivery creates a high RSI floor similar to other premium healthcare compounders. RSI dips to 45-48 during broad healthcare selloffs. Where animal health fundamentals are completely unaffected by human insurance policy. Have been some of the most reliable sector-rotation-driven entry points in the past five years. APEX scores ZTS's RSI as part of its 8-factor composite signal. Updated daily.

QHow does ZTS behave technically compared to other Healthcare / Animal Health stocks?

AZTS is in the Healthcare / Animal Health sector. Zoetis is the world's largest animal health company. A Pfizer spin-off. Developing vaccines, medicines, and diagnostic tools for livestock and companion animals (dogs, cats, horses). Its companion animal business (drugs for pets) has grown dramatically with pet ownership trends and the humanization of pets. Simparica Trio (flea, tick, and heartworm prevention) and Cytopoint (atopic dermatitis treatment) are blockbuster products with $1B+ annual sales. The livestock segment serves poultry, swine, and cattle producers globally. Key stats: ATR (14-day): 2-4% of price, Avg daily volume: ~2-4 million shares, Key metric: Companion animal revenue growth, Post-earnings move: 4-7% typical.

QWhat MACD signals work best for ZTS?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks ZTS's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−